SCHEMBL493689

SCHEMBL493689

CN(CCOCC(=O)NC1CCC(C(c2ccccc2)N2CCCC2)CC1)S(=O)(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 1/20 0.37
CACNA1B Q00975 1/20 0.37
CACNB1 Q02641 1/20 0.37
CACNA1C Q13936 1/20 0.37
ALDH1A1 P00352 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 2/20 0.37
RAB9A P51151 2/20 0.37
POLB P06746 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
MCHR1 Q99705 1/20 0.36
BDKRB1 P46663 2/20 0.36
SIGMAR1 Q99720 1/20 0.36
MAPT P10636 1/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL493216 0.94 CACNA2D1 (0.43) CACNA2D1CACNA1BCACNB1CACNA1CCNR1
SCHEMBL492771 0.94 MEN1 (0.38) CACNA2D1CACNA1BCACNB1CACNA1CSMN1; SMN2
SCHEMBL492975 0.91 CACNA2D1 (0.37) CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1
SCHEMBL492596 0.90 ALDH1A1 (0.37) CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1
SCHEMBL492927 0.90 CACNA2D1 (0.36) CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1
SCHEMBL492867 0.88 BDKRB1 (0.39) CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1
SCHEMBL492458 0.87 MAPT (0.38) ALDH1A1SMN1; SMN2LMNARAB9AMEN1
SCHEMBL493134 0.86 MCHR1 (0.38) ALDH1A1SMN1; SMN2LMNARAB9APOLB
SCHEMBL493117 0.85 CACNA2D1 (0.42) CACNA2D1CACNA1BCACNB1CACNA1CBDKRB1
SCHEMBL493360 0.85 LMNA (0.39) ALDH1A1SMN1; SMN2LMNATDP1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US claimed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP claimed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US claimed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO claimed
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US disclosed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP disclosed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US disclosed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306084-A1 Substituted Amide Compounds OPRK1, NAA50, ACMSD CACNA2D1 638/4885CACNA1B 1416/4885CACNB1 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.